Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

Mizuho Neuro & Ophthalmology Summit 2025
Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET

Jefferies Global Healthcare Conference
Presentation: Thursday, June 5, 2025, at 1:25 p.m. ET

The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]

Media Contact:
Cheryl Wheeler
Head of Corporate Communications
[email protected]
        

Source: Collegium Pharmaceutical, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Brixton Metals Announces Closing Of Second Tranche Of Its Private Placement
• Osisko Gold Announces CFO Transition to Support Its Next Stage of Growth
• Advasa Holdings, Inc. completed a direct listing on Nasdaq under the ticker symbol "ADBT"